



Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

Amendment Pursuant to 37 C.F.R. § 1.121

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. (Previously presented) A compound of formula (1) or formula (2)



wherein:

X and Y are N;

Ar is:

phenyl optionally substituted with one or more substituents selected from the group consisting of: halogen, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, thio(C₁-C₄)alkyl, NO₂, NH(C₁-C₄)alkyl and N((C₁-C₄)alkyl)₂ wherein said alkyl may optionally form a 4 to 6 membered ring together with the heteroatom to which it is attached and an ortho carbon of the phenyl wherein said 4 to 6 membered ring may contain a second hetero atom selected from the group consisting of O, S and N,

Z is H, 4-aminophenyl, SO₂R₃ or COR₃ wherein R₃ is (C₁-C₄)alkyl,

(C₃-C₆)cycloalkyl, Ar as defined above, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

R₁ is H, (C₁-C₄)alkyl, (C₃-C₆)cycloalkyl or Ar as defined above;

R' is H or (C₁-C₄)alkyl; and

when Z is H, R₂ is selected from the group consisting of:

ST01021 US CNT

-2 of 12-

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

cyano,

C(O)-ORa₁ wherein Ra₁ is methyl, ethyl or isopropyl,

C(O)-NHRa₂ wherein Ra₂ is cyclopropyl,

C(O)-N(Ra₂'), wherein N(Ra₂') is aziridinyl or azetidiny, optionally substituted with (C₁-C₄)alkyl or Ar as defined above,

C(O)-N(Ra₃)-ORa₃ wherein each Ra₃ may be identical or different and each Ra₃ is independently selected from the group consisting of methyl, ethyl or cyclopropyl,

C(O)Ra₄ wherein Ra₄ is Ar as defined above or (C₃-C₅)cycloalkyl optionally substituted with (C₁-C₄)alkyl or Ar as defined above,

C(Ra₄)=N-Rb wherein:

Ra₄ is H, Ar as defined above, or (C₃-C₅)cycloalkyl optionally substituted with (C₁-C₄)alkyl or Ar as defined above, and Rb is (C₁-C₂)alkyl, (C₃-C₅)cycloalkyl, hydroxyl, (C₁-C₄)alkoxy, (C₂-C₄)alkenyloxy, or (C₁-C₄)alkylenoxy wherein said (C₁-C₄)alkylenoxy optionally may be substituted with halogen or a group selected from the group consisting of carboxyl, (CH₂)_nAr wherein n is 0 or 1 and Ar is as defined above, (C₁-C₄)alkoxy, NH₂, NH(C₁-C₄)alkyl, and N((C₁-C₄)alkyl)₂ wherein said alkyls together with the heteroatom to which they are attached may optionally form a 3 to 6 membered ring which may optionally contain a second hetero atom selected from the group consisting of O, S and N,

NH-C(O)Ra₄ wherein Ra₄ is H, Ar as defined above, or (C₃-C₅)cycloalkyl optionally substituted with (C₁-C₄)alkyl or Ar as defined above,

NHRa₄ wherein Ra₄ is H, Ar as defined above, or (C₃-C₅)cycloalkyl optionally substituted with (C₁-C₄)alkyl or Ar as defined above,

phenyl, and

5 to 6 membered aromatic heterocycle containing 1 to 3 hetero atoms selected from the group consisting of O, N and S; and

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

when Z is SO_2R_3 or COR_3 , R_2 is carboxyl, NH_2 , $\text{NH}(\text{C}_1\text{-C}_4)\text{alkyl}$, $\text{N}((\text{C}_1\text{-C}_4)\text{alkyl})_2$ or $(\text{C}_3\text{-C}_5)\text{cycloalkylamino}$; or
a stereoisomeric form of the compound of formula (1) or formula (2), or mixtures of the stereoisomeric forms thereof in any ratio; or
a pharmaceutically acceptable salt of the compound of formula (1) or formula (2).

2. (Original) The compound according to claim 1 wherein Ar is phenyl, 4-fluorophenyl or 4-methoxyphenyl.

3. (Original) The compound according to claim 2 wherein R_1 is H, $(\text{C}_1\text{-C}_4)\text{alkyl}$, phenyl or substituted phenyl.

4. (Canceled).

5. (Previously presented) The compound according to claim 3 wherein R_2 is $\text{C}(\text{O})\text{-ORa}_1$ and wherein Ra_1 is methyl, ethyl or isopropyl.

6. (Original) The compound according to claim 5 selected from the group consisting of:

ethyl 6,6-diphenyl-6,7-dihydro-2H-indazole-3-carboxylate,
isopropyl 6,6-diphenyl-6,7-dihydro-2H-indazole-3-carboxylate,
methyl 6,6-diphenyl-6,7-dihydro-2H-indazole-3-carboxylate,
ethyl 6-(R,S)-6-methyl-6-phenyl-6,7-dihydro-1H-indazole-3-carboxylate,
ethyl 6-(+)-6-methyl-6-phenyl-6,7-dihydro-1H-indazole-3-carboxylate,
ethyl 6-(R,S)-6-phenyl-6,7-dihydro-2H-indazole-3-carboxylate,
ethyl 6-(R)-6-phenyl-6,7-dihydro-2H-indazole-3-carboxylate,
ethyl 6-(S)-6-phenyl-6,7-dihydro-2H-indazole-3-carboxylate,

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

ethyl 6,6-bis(4-methoxyphenyl)-6,7-dihydro-1H-indazole-3-carboxylate,
ethyl 6-(R,S)-6-(3,4-dimethoxyphenyl)-6-phenyl-6,7-dihydro-1H-indazole-3-carboxylate,
ethyl 6-(R,S)-6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazole-3-carboxylate,
ethyl (-)-6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazole-3-carboxylate,
ethyl (+)-6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazole-3-carboxylate,
ethyl 6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazole-3-carboxylate, and
ethyl 7-methyl-6,6-diphenyl-6,7-dihydro-1H-indazole-3-carboxylate.

7. (Previously presented) The compound according to claim 3 wherein R_2 is $CORa_4$ and Ra_4 is Ar or (C_3-C_5) cycloalkyl.

8. (Original) The compound according to claim 7 selected from the group consisting of:

cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone,
cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone,
(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)phenylmethanone,
(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)-(1H-pyrrol-3-yl)methanone,
6-(R,S)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone,
(-)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone,
(+)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone, and

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

cyclopropyl[6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazol-3-yl]methanone.

9. (Previously presented) The compound according to claim 3 wherein R_2 is $C(O)-NHR_2$, $C(O)-N(R_3)-OR_3$ or $C(O)-N(R_2)$.

10. (Original) The compound according to claim 9 selected from the group consisting of:

N-(cyclopropyl)-6,6-diphenyl-6,7-dihydro-1H-indazole-3-carboxamide,
azetidin-1-yl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone,
(N-methoxy-N-methyl)-6,6-diphenyl-6,7-dihydro-1H-indazole-3-carboxamide, and
aziridin-1-yl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone.

11. (Previously presented) The compound according to claim 3 wherein R_2 is $C(R_4)=N-R_b$.

12. (Original) The compound according to claim 11 selected from the group consisting of:

(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone oxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone oxime,
(E,Z)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone oxime,
(E)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone oxime,

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

(Z)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone oxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-2H-indazol-3-yl)methanone O-methyloxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-2H-indazol-3-yl)methanone O-methyloxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-2H-indazol-3-yl)methanone O-methyloxime,
(E,Z)6,6-diphenyl-6,6-dihydro-1H-indazole-3-carbaldehyde O-methyloxime,
(E, Z)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-allyloxime,
(E)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-allyloxime,
(Z)cyclobutyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-allyloxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-allyloxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-allyloxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-allyloxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(2-methoxyethyl)oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(2-methoxyethyl)oxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-(2-methoxyethyl)oxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone O-benzyloxime,

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-benzyloxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-benzyloxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-
yl)methanone O-(4-nitrobenzyl)oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-(4-nitrobenzyl)oxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-(4-nitrobenzyl)oxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-
yl)methanone O-(2-dimethylaminoethyl)oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-(2-dimethylaminoethyl)oxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-(2-dimethylaminoethyl)oxime,
(E,Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-
yl)methanone O-(2-fluoroethyl)oxime,
(Z)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-(2-fluoroethyl)oxime,
(E)cyclopropyl(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)methanone
O-(2-fluoroethyl)oxime,
(E,Z)-6-(R,S)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-
1H-indazol-3-yl]methanone oxime,
(E)-6-(R,S)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-
indazol-3-yl]methanone oxime,
(Z)-6-(R,S)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-
indazol-3-yl]methanone oxime,
(-)-6-(Z)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-
indazol-3-yl]methanone oxime,

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

(-)-6-(E)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone oxime,
(+)-6-(Z)-cyclopropyl[6-(4-fluorophenyl)-6-phenyl-6,7-dihydro-1H-indazol-3-yl]methanone oxime,
(E,Z)cyclopropyl[6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazol-3-yl]methanone oxime,
(Z)cyclopropyl[6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazol-3-yl]methanone oxime, and
(E)cyclopropyl[6,6-bis(4-fluorophenyl)-6,7-dihydro-1H-indazol-3-yl]methanone oxime.

13. (Previously presented) The compound according to claim 3 wherein R_2 is NH-C(O)Ra_4 .

14. (Previously presented) The compound according to claim 13 selected from the group consisting of:

N-(6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl)cyclopropylamide, and
N-[6,6-diphenyl-6,7-dihydro-1H-indazol-3-yl]benzamide.

15. (Previously presented) The compound according to claim 3 wherein R_2 is phenyl, pyridyl, oxadiazolyl or thiophenyl.

16. (Original) The compound according to claim 15 selected from the group consisting of:

3-(3-methyl[1,2,4]oxadiazol-5-yl)-6,6-diphenyl-6,7-dihydro-1H-indazole,
3,6,6-triphenyl-6,7-dihydro-1H-indazole,
6,6-diphenyl-3-pyrid-3-yl-6,7-dihydro-1H-indazole, and
6,6-diphenyl-3-thiophen-3-yl-6,7-dihydro-1H-indazole.

Application Ser. No.: 10/761,982
Filing Date: January 21, 2004
Examiner: Stockton, Laura

17. (Previously presented) The compound according to claim 3 wherein R_2 is CN.

18. (Previously presented) The compound according to claim 17 wherein the compound is 6,6-diphenyl-6,7-dihydro-1H-indazole-3-carbonitrile.

19. (Original) The compound according to claim 1 wherein Z is SO_2R_3 or COR_3 .

20. (Original) The compound according to claim 19 selected from the group consisting of:

6,6-diphenyl-1-(4-toluenesulphonyl)-6,7-dihydro-1H-indazol-3-ylamine and
1-(3-amino-6,6-diphenyl-6,7-dihydroindazol-1-yl)propenone.

21. (Original) The compound according to claim 1 wherein Z is 4-aminophenyl.

22. (Original) The compound according to claim 21 wherein the compound is ethyl 1-(4-aminophenyl)-6,6-diphenyl-1H-indazole-3-carboxylate.

23. – 34. (Canceled).

35. (Original) A pharmaceutical composition comprising one or more compounds of formula (1) or formula (2) according to claim 1 and one or more pharmaceutically acceptable carriers, diluents, adjuvants or excipients.